Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02400242 · ClinicalTrials.gov registry record · Phase 1
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT02400242: Clinical Trial Phase 1 study, sponsored by Celgene.
NCT02400242 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02400242, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomide and low-dose dexamethasone in eligible patients with relapsed or relapsed-and-refractory multiple myeloma (MM).
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG ACY-241
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2015-05-07 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 1 |
Why NCT02400242 stopped before completion
NCT02400242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02400242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02400242 about?
NCT02400242 is a clinical study titled "Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma". This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor activity of ACY-241 for oral administration as monotherapy and in combination therapy with orally administered pomalidomid...
What is the current status of trial NCT02400242?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2015-05-07. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT02400242?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), ACY-241 (DRUG).
Who is sponsoring clinical trial NCT02400242?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02400242's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI